FDA approves Nuvalent lung cancer drug shortly after GSK completes $10.6 billion acquisition
The FDA announced Wednesday that it has approved a lung cancer medicine from Nuvalent, marking a key regulatory milestone for the biotech.
The clearance arrived just a week after GlaxoSmithKline closed its $10.6 billion purchase of Nuvalent, underscoring the rapid integration of the acquired pipeline.
The drug was approved two months earlier than Nuvalent had originally projected, suggesting an accelerated development timeline under GSK ownership.
Analysts see the early approval as a positive signal for investors and may speed up further clinical programs within the combined company.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that